Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
Abbott received FDA approval for new patient-facing capabilities in its CardioMEMS HF System, allowing U.S. patients to view their pulmonary artery pressure readings via the CardioGuide HF App for the first time. The update also includes Dynamic Treatment Plan, a Merlin.net feature enabling clinicians to push personalized medication-adjustment instructions directly to patients through the app.
Key figures
- Drug Name
- CardioMEMS HF System
- Feature availability
- CardioGuide HF App and Dynamic Treatment Plan available later this year
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.